Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Urothelial04 adjuvant Dato-DXd ± rilvegostomig versus standard-of-care in high-risk muscle invasive urothelial carcinoma after radical resection
jRCT2041260098Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Randomised trial in transitional cell carcinoma (TCC) comparing Dato-DXd + rilvegostomig, Dato-DXd monotherapy and Standard-of-care (3 arms). Primary endpoint: Disease-free survival. Started Aug 2026; status: recruiting.
02
Drugs
datopotamab deruxtecanrilvegostomig
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2041260098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260098.